6533b856fe1ef96bd12b1da3
RESEARCH PRODUCT
Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer
Ricard BorrásSusana RosellóAndrés Cervantessubject
OncologyDrugmedicine.medical_specialtyChemotherapybiologyBevacizumabbusiness.industryColorectal cancermedicine.medical_treatmentmedia_common.quotation_subjectmedicine.diseaseDisease controlText miningEditorialInternal medicinebiology.proteinMedicineSingle agentAntibodybusinessmedia_commonmedicine.drugdescription
The availability of biologicals, such as anti-EFGR and anti-VEGF antibodies in combination with chemotherapy (ChT), has improved prognosis of metastatic colorectal cancer (mCRC). However, the administration of drug combinations for a prolonged time implies an increased rate of toxicities, which is why some strategies to de-escalate treatment intensity have been studied.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-09-01 |